Seeking Alpha

Celgene's (CELG -0.1%) Apremilast drug significantly improved the signs and symptoms of patients...

Celgene's (CELG -0.1%) Apremilast drug significantly improved the signs and symptoms of patients with psoriatic arthritis in the company's "Palace 3" Phase III study. The results come a day after Celgene reported a positive outcome from "Palace I". In total, the company is conducting four Phase III "Palace" trials. (PR)
Comments (1)
  • somewhat expected, but should have a beneficial effect on FDA approval. As a non-biologic, it has other treatment merits as well.
    13 Jun 2013, 02:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)